Fayza A. Hassan
Cairo University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Fayza A. Hassan.
Clinical Biochemistry | 2014
Laila Selim; Sawsan Hassan; Fadia Salem; Azza Orabi; Fayza A. Hassan; Fatma El-Mougy; Iman G. Mahmoud; Amira El-Badawy; Marian Y. Girgis; Mohammed A Elmonem; Dina Mehaney
OBJECTIVE In order to enhance awareness and promote registry for inborn errors of metabolism (IEMs) in Egypt, we aimed to evaluate the prevalence and main clinical findings of IEMs detectable by tandem mass spectrometry (MS/MS) among high risk pediatric patients presenting to our tertiary care facility at Cairo University Childrens Hospital over a period of 5 years and to compare the disease burden in Egypt in the absence of a national screening program for inherited metabolic disorders with other populations. METHODS During this period 3380 Egyptian children were suspected of having IEMs based on clinical/laboratory presentation and were analyzed by MS/MS. Confirmatory testing was performed according to flagged analyte by MS/MS using a different sample type such as plasma or urine or by a different technique such as GC/MS. RESULTS A relatively high number of patients (203/3380 (6%)) were confirmed with 17 different types of IEMs. Averages for age at diagnosis for different disorders ranged from 2.5 months to 6.6 years with general developmental delay and irreversible neurological damage being the most common presenting features (75.9% and 65.5%, respectively). Amino acid disorders (127/203 (62.6%)), mainly phenylketonuria (100/203 (49.3%)), were the most encountered, followed by organic acidemias (69/203 (34%)), while fatty acid oxidation defects (7/203 (3.4%)) were relatively rare. 88% of patients were born to consanguineous parents. CONCLUSIONS The development of a nationwide screening program for IEMs is mandatory for early detection of these potentially treatable disorders, prompt and properly timed therapeutic intervention and prevention of the devastating neurological outcomes.
Journal of Medical Screening | 2016
Fayza A. Hassan; Fatma El-Mougy; Sahar Sharaf; Iman Atef Mandour; Marian F Morgan; Laila Selim; Sawsan Hassan; Fadia Salem; Azza Oraby; Marian Y. Girgis; Iman G. Mahmoud; Amira El-Badawy; Ibrahim El-Nekhely; Nadia Moharam; Dina Mehaney; Mohamed A. Elmonem
Objectives To estimate the burden of metabolic disorders detectable by tandem mass spectrometry in Egypt, through a pilot expanded newborn screening programme at Cairo University Childrens Hospital in 2008, and examining the results of 3,900 clinically at-risk children, investigated at Cairo University Children’s Hospital for the same disorders over the past 7 years using the same technology. Methods Dried blood spots of 25,276 healthy newborns from three governorates in Upper, Middle, and Lower Egypt were screened, to give a representative sample of the Egyptian newborn population. Based on the pilot study outcomes and the results of clinically suspected children, we estimated the total birth prevalence of tandem mass spectrometry detectable metabolic disorders, and the relative frequency of several individual disorders. Results Among the healthy newborns, 13 metabolic disorder cases (five phenylketonuria [1:5,000], two methylmalonic acidemia, and isovaleric acidemia [1:12,500], one each of maple syrup urine disease, propionic acidemia, β-ketothiolase deficiency, and primary carnitine deficiency [1:25,000]) were confirmed, giving a total birth prevalence of 1:1944 live births. Among the clinically suspected children, 235 cases were diagnosed, representing a much wider disease spectrum. Conclusions Egypt has one of the highest reported birth prevalence rates for metabolic disorders detectable by tandem mass spectrometry. Early diagnosis and management are crucial for the survival and well-being of affected children. A nationwide NBS programme by tandem mass spectrometry is recommended.
Indian Pediatrics | 2014
Mona M. Fathy; Noha M. Abdelrazek; Fayza A. Hassan; Ayman A. El-Badry
ObjectiveTo determine molecular prevalence of Cryptosporidium in a cohort of Egyptian children and compare three diagnostic tests.MethodsStool samples from children with diarrhea (n=150) and from apparently healthy children (n=100) were examined for Cryptosporidium using microscopy, enzyme linked immuosorbant assay (ELISA) and nested polymerase chain reaction (nPCR).ResultsnPCR detected Cryptosporidium in 22.4% of children. Acid-fast stain and ELISA showed false negativity but 100% specificity with nPCR as gold standard.ConclusionCryptosporidium is a common cause of diarrhea in children in Egypt.
Andrologia | 2016
M. Fathy; T. Ramzy; M. A. Elmonem; Medhat Amer; A. Zeidan; Fayza A. Hassan; D. A. Mehaney
In the current study, we enrolled 14 Egyptian infertile males with isolated congenital bilateral absence of the vas deferens (CBAVD). Screening for the most commonly reported 36 CFTR mutations, and the intron 8 (T)n splice variant was performed by multiplex PCR followed by reversed hybridisation. Samples with the 5T variant were picked for DNA sequencing of intron 8/exon 9 region to identify the number of adjacent TG repeats. The p.Phe508del and the p.Ser1251Asn mutations were detected in heterozygous state in three patients (10.7% of alleles) and in one patient (3.6% of alleles), respectively, while the 5T variant was detected in five patients (28.6% of alleles). Among those five patients, four had TG12 repeats and one had TG13 repeats confirming the pathogenic penetrance of all 5T alleles in Egyptian CBAVD patients. The allelic frequencies of the mutations p.Phe508del, p.Ser1251Asn and the 5T variant in 60 Egyptian cystic fibrosis patients were 24.2%, 3.3% and 2.5% respectively. The mutation p.Ser1251Asn was detected for the first time in isolated CBAVD patient in our study. Due to the high prevalence of p.Phe508del mutation and 5T variant in Egyptian CBAVD patients, we recommend their screening initially, ideally followed by full CFTR gene sequencing in unidentified patients.
Orphanet Journal of Rare Diseases | 2014
Mohamed A. Elmonem; Samuel H Makar; Lambertus P. van den Heuvel; Hanan Abdelaziz; Safaa M. Abdelrahman; Xavier Bossuyt; M. Janssen; Elisabeth A. M. Cornelissen; Dirk J. Lefeber; Leo A. B. Joosten; Marwa M. Nabhan; Fanny Oliveira Arcolino; Fayza A. Hassan; Héloïse P. Gaide Chevronnay; Neveen A. Soliman; Elena Levtchenko
Orphanet Journal of Rare Diseases | 2014
Mohamed Ibrahim; Samuel H Makar; Bert van den Heuvel; Hanan Abdelaziz; Safaa M. Abdelrahman; Xavier Bossuyt; M. Janssen; Elisabeth A. M. Cornelissen; Dirk J. Lefeber; Leo A. B. Joosten; Marwa M. Nabhan; Fanny Oliveira Arcolino; Fayza A. Hassan; Héloïse P. Gaide Chevronnay; Neveen A. Soliman; Elena Levtchenko
the egyptian journal of medical human genetics | 2012
Laila Selim; Dina Mehaney; Fayza A. Hassan; Randa Sabry; Reham Zeyada; Sawsan Hassan; Iman Gamal Eldin; Enrico Bertini
Comparative Haematology International | 2012
Fayza A. Hassan; Marianne F. Morgan; Dina F. Elgayar; Dina El-Abd; Riham A. El-Essawy
Pediatric Nephrology | 2013
Mohamed A. Elmonem; Samuel H Makar; Rehab H Abdelhamid; Bert van den Heuvel; Xavier Bossuyt; Fayza A. Hassan; Neveen A. Soliman; Elena Levtchenko
Journal of Genetic Engineering and Biotechnology | 2013
Laila Selim; Dina Mehaney; Fayza A. Hassan; Sawsan Hassan; Iman Gamaleldin; Randa Sabry; Enrico Bertini